GTHX vs. RIGL, ABUS, ANAB, SAGE, MLYS, RNAC, LYEL, HROW, DNTH, and ANNX
Should you be buying G1 Therapeutics stock or one of its competitors? The main competitors of G1 Therapeutics include Rigel Pharmaceuticals (RIGL), Arbutus Biopharma (ABUS), AnaptysBio (ANAB), Sage Therapeutics (SAGE), Mineralys Therapeutics (MLYS), Cartesian Therapeutics (RNAC), Lyell Immunopharma (LYEL), Harrow (HROW), Dianthus Therapeutics (DNTH), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
G1 Therapeutics (NASDAQ:GTHX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than G1 Therapeutics. MarketBeat recorded 4 mentions for Rigel Pharmaceuticals and 2 mentions for G1 Therapeutics. G1 Therapeutics' average media sentiment score of 0.97 beat Rigel Pharmaceuticals' score of 0.30 indicating that G1 Therapeutics is being referred to more favorably in the media.
Rigel Pharmaceuticals received 142 more outperform votes than G1 Therapeutics when rated by MarketBeat users. Likewise, 68.90% of users gave Rigel Pharmaceuticals an outperform vote while only 66.10% of users gave G1 Therapeutics an outperform vote.
Rigel Pharmaceuticals has higher revenue and earnings than G1 Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.
G1 Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
24.2% of G1 Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.1% of G1 Therapeutics shares are held by insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Rigel Pharmaceuticals has a net margin of -16.45% compared to G1 Therapeutics' net margin of -36.40%. Rigel Pharmaceuticals' return on equity of 0.00% beat G1 Therapeutics' return on equity.
G1 Therapeutics currently has a consensus price target of $8.67, indicating a potential upside of 187.93%. Rigel Pharmaceuticals has a consensus price target of $5.81, indicating a potential upside of 511.84%. Given Rigel Pharmaceuticals' higher probable upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than G1 Therapeutics.
Summary
Rigel Pharmaceuticals beats G1 Therapeutics on 12 of the 17 factors compared between the two stocks.
Get G1 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
G1 Therapeutics Competitors List
Related Companies and Tools
